Orthotopic liver transplantation in dogs receiving FK-506.

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.

OBJECTIVE The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agent, FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), was determined. SUMMARY BACKGROUND DATA After 3 years of preclinical research, a clinical trial of FK 506 for orthotopic liver transplantation was begun in February 1989, first as a rescue therapy for patients with intractable rejecti...

Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

Pharmacokinetics of FK 506: preclinical and clinical studies.

FK 506 is a macrolide with potent immunosuppressive effects. Its immunosuppressive property has been documented in both in vitro! lymphocyte proliferation studies and in vivo studies. FK 506 treatment significantly prolongs graft survival in rats receiving heterotopic heart transplants. dogs receiving kidneys or livers. and baboons receiving kidney transplants.2 Currently, FK 506 is undergoing ...

HLA-DR matching effect in orthotopic liver transplantation under FK 506.

U NLIKE in kidney transplantation, graft survival was not influenced by the degree of HLA matching in human liver transplantation. In fact, our preliminary results revealed that 0 DR-matched liver transplant patients had inferior graft survival rates compared with those of 1 or 2 DR-mismatched transplants. 1 FK 506 is a new, powerful immunosuppressant, and it is effective for both liver and kid...

One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

FK 506 (Tanolimus. Prograf'") has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1989. 1 and I year later at the Thirteenth International Congress of Transplantation Society. San Francisco. CA 1990. extensive reports were given from our center describing the p...